Mirae Asset Global Investments Co., Ltd. Anavex Life Sciences Corp. Transaction History

Mirae Asset Global Investments Co., Ltd.

$22.5 Billion
Q3 2024

A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 3,067 shares of AVXL stock, worth $27,940. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,067

Previous 2,527 21.37%

Holding current value

$27,940

Previous $10,000 70.0%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 23, 2024	BUY	$4.11 - $7.04 $2,219 - $3,801	540 Added 21.37%	3,067 $17,000
Q2 2024 Jul 30, 2024	SELL	$3.39 - $5.02 $177,374 - $262,661	-52,323 Reduced 95.39%	2,527 $10,000
Q1 2024 May 01, 2024	BUY	$4.55 - $6.75 $57,912 - $85,914	12,728 Added 30.22%	54,850 $279,000
Q4 2023 Jan 24, 2024	SELL	$5.04 - $9.95 $3,442 - $6,795	-683 Reduced 1.6%	42,122 $392,000
Q3 2023 Oct 26, 2023	SELL	$6.55 - $9.37 $20,874 - $29,862	-3,187 Reduced 6.93%	42,805 $280,000
Q2 2023 Aug 10, 2023	SELL	$7.66 - $9.5 $43,907 - $54,454	-5,732 Reduced 11.08%	45,992 $373,000
Q1 2023 May 04, 2023	BUY	$8.32 - $11.75 $146,257 - $206,553	17,579 Added 51.48%	51,724 $443,000
Q4 2022 Feb 09, 2023	BUY	$7.65 - $14.43 $34,478 - $65,036	4,507 Added 15.21%	34,145 $316,000
Q3 2022 Nov 10, 2022	BUY	$8.9 - $12.86 $76,904 - $111,123	8,641 Added 41.15%	29,638 $306,000
Q2 2022 Jul 26, 2022	BUY	$7.31 - $12.84 $153,488 - $269,601	20,997 New	20,997 $210,000

Others Institutions Holding AVXL

# of Institutions

154

Shares Held

27.3M

Call Options Held

515K

Put Options Held

838K

View Full List

About ANAVEX LIFE SCIENCES CORP.

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $710M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

More about AVXL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Account

Mirae Asset Global Investments Co., Ltd. Anavex Life Sciences Corp. Transaction History